Jiménez Flores, Lizbeth Minerva (Date of defense: 2018-11-09)
Gastric cancer (GC) is one of the most common types of cancer in the Western World and accounts for over 700,000 deaths every year worldwide. The prognosis is dismal, with an average 5-year survival ...
Banús Mulet, Antònia (Date of defense: 2019-07-16)
Recentment s’han descrit els receptors de dopamina per la seva implicació en càncer i la seva potencial inhibició com a mecanisme antitumoral. Al present treball s’ha ampliat aquesta recerca a la LLA-T, ...
Benítez, Sandra (Date of defense: 2021-01-13)
Receptor activator of nuclear factor kappa-β ligand (RANKL) and its receptor RANK are key mediators of bone resorption1,2. RANKL, its receptor RANK and its natural decoy receptor OPG, which is a competitive ...
Gómez González, Soledad (Date of defense: 2017-09-21)
Evidencias recientes han mostrado que los tumores sólidos pediátricos, incluidos el neuroblastoma y el meduloblastoma, albergan una baja cantidad de mutaciones genéticas recurrentes, pero presentan una ...
Montero Martín, Sara (Date of defense: 2021-11-22)
Despite the latest advances in early diagnosis and increased resources employed to develop new therapeutic options, effective control of cancer disease remains a challenge. In fact, cancer is the second ...
Palau de Miguel, Anna (Date of defense: 2016-11-30)
Polycomb proteins are important epigenetic regulators involved in the maintenance of stemness and differentiation. In this thesis, I focused on the role of some Polycomb Repressive Complex 1 (PRC1) ...
Albert Colomer, Nerea (Date of defense: 2021-01-18)
Tumor-stroma crosstalk is essential for PDAC formation. Therefore, the stroma, and specifically the carcinoma-associated fibroblasts (CAFs), are the target of therapeutic alternatives to treat highly ...
Bernat Peguera, Adrià (Date of defense: 2019-09-20)
La mayoría de los carcinomas escamosos de piel (cSCCs) se tratan con éxito mediante escisión quirúrgica. Sin embargo, el 5-8% de los casos desarrollan recurrencias, las cuales están asociadas a un ...
Riera Armengol, Pau (Date of defense: 2020-09-23)
El càncer colorectal (CCR) és una neoplàsia molt freqüent que causa una elevada mortalitat arreu del món. Els fàrmacs més utilitzats en el seu maneig són quimioteràpics (fluoropirimidines, oxaliplatí i ...
Ramírez Corpas, Lorena (Date of defense: 2023-01-20)
[spa] Alrededor del 10% de los pacientes con cáncer colorrectal metastático (mCRC) presentan la mutación BRAF(V600E), mutación que está asociada a una peor respuesta al tratamiento estándar con agentes ...